Outcome of atypical hemolytic uremic syndrome: role of triggers and complement abnormalities in the response to C5 inhibition.
C5inhibition
Complement abnormalities
Complement dysregulation
aHUS
Journal
Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268
Informations de publication
Date de publication:
27 Jan 2024
27 Jan 2024
Historique:
received:
10
08
2023
accepted:
26
12
2023
medline:
28
1
2024
pubmed:
28
1
2024
entrez:
27
1
2024
Statut:
aheadofprint
Résumé
Atypical-hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy often due to uncontrolled complement activation, characterized by high risk of end-stage kidney disease (ESKD). Eculizumab has improved the outcome, however, its efficacy varies among patients and its discontinuation is debated. To identify characteristics associated with treatment response, we analyzed 244 aHUS patients referred to our center. Patients were classified according to the presence/absence of complement abnormalities and/or triggers at onset in 4 categories: (1) primary (complement abnormality without trigger), (2) secondary (trigger without complement abnormality), (3) combined (trigger and complement abnormality), (4) idiopathic (no trigger, no complement abnormality). Response to treatment was evaluated by comparing the response to eculizumab with that of conventional therapy. Short- and long-term outcomes were evaluated with the relapse rate after discontinuation of C5-inhibition. Patients had a better outcome with eculizumab compared to conventional treatment, with a response rate of 81.9% vs 56.9%, p < 0.001 and a long-term cumulative incidence of ESKD of 5.8% vs 22.5% (hazard ratio 0.25, 95% confidence interval: 0.10-0.80). The excellent global response was driven by the primary and combined groups (89.8% vs 54.0% and 89.3% vs 54.2%, respectively). The relapse rate following discontinuation of the C5-inhibitor was as high as 66.7% in the primary group, 18.7% in the combined, and 0% in the secondary and idiopathic groups. Our data show a better outcome in aHUS patients treated with C5-inhibition, particularly in the primary and combined forms, which have a high risk of relapse after discontinuation that is not observed in the secondary and idiopathic forms.
Sections du résumé
BACKGROUND
BACKGROUND
Atypical-hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy often due to uncontrolled complement activation, characterized by high risk of end-stage kidney disease (ESKD). Eculizumab has improved the outcome, however, its efficacy varies among patients and its discontinuation is debated.
METHODS
METHODS
To identify characteristics associated with treatment response, we analyzed 244 aHUS patients referred to our center. Patients were classified according to the presence/absence of complement abnormalities and/or triggers at onset in 4 categories: (1) primary (complement abnormality without trigger), (2) secondary (trigger without complement abnormality), (3) combined (trigger and complement abnormality), (4) idiopathic (no trigger, no complement abnormality). Response to treatment was evaluated by comparing the response to eculizumab with that of conventional therapy. Short- and long-term outcomes were evaluated with the relapse rate after discontinuation of C5-inhibition.
RESULTS
RESULTS
Patients had a better outcome with eculizumab compared to conventional treatment, with a response rate of 81.9% vs 56.9%, p < 0.001 and a long-term cumulative incidence of ESKD of 5.8% vs 22.5% (hazard ratio 0.25, 95% confidence interval: 0.10-0.80). The excellent global response was driven by the primary and combined groups (89.8% vs 54.0% and 89.3% vs 54.2%, respectively). The relapse rate following discontinuation of the C5-inhibitor was as high as 66.7% in the primary group, 18.7% in the combined, and 0% in the secondary and idiopathic groups.
CONCLUSIONS
CONCLUSIONS
Our data show a better outcome in aHUS patients treated with C5-inhibition, particularly in the primary and combined forms, which have a high risk of relapse after discontinuation that is not observed in the secondary and idiopathic forms.
Identifiants
pubmed: 38280096
doi: 10.1007/s40620-023-01873-9
pii: 10.1007/s40620-023-01873-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Acaia Barbara
(A)
Aiuti Alessandro
(A)
Alfieri Carlo
(A)
Amar Karen
(A)
Atzeni Alice
(A)
Basolo Bruno
(B)
Bernardo Maria
(B)
Biffi Alessandra
(B)
Brezzi Brigida
(B)
Brigante Maurizio
(B)
Bucalossi Alessandro
(B)
Calbi Valeria
(C)
Caroti Leonardo
(C)
Carotti Alessandra
(C)
Casani Aldo
(C)
Casartelli Donatella
(C)
Cassata Nicola
(C)
Castiglioni Alessandro
(C)
Catalano Francesco
(C)
Chiarinotti Doriana
(C)
Cirami Calogero
(C)
Colussi Giacomo
(C)
Corrado Ciro
(C)
Costantini Luigia
(C)
Cravero Raffaella
(C)
Credendino Olga
(C)
D 'Amico Marco
(D')
Davoli Delia
(D)
De Biase
De Philippis
Decembrino Nunzia
(D)
Del Vecchio
(D)
Facchini Luca
(F)
Fenoglio Roberta
(F)
Ferrantelli Angelo
(F)
Ferrara Domenico
(F)
Fischer Maria
(F)
Floreani Riccardo
(F)
Furian Lucrezia
(F)
Galassi Andrea
(G)
Gambaro Giovanni
(G)
Giglio Fabio
(G)
Giordano Mario
(G)
Gregorini Gina
(G)
Iannuzzella Francesco
(I)
Inzoli Alessandro
(I)
La Scola
Longhi Selena
(L)
Marangelli Annunziata
(M)
Marcantoni Carmelita
(M)
Marinelli Rita
(M)
Maringhini Silvio
(M)
Mariotti Jacopo
(M)
Marktel Sarah
(M)
Marta Verna
(M)
Martelli Laura
(M)
Martini Marco
(M)
Mehemeti Florjan
(M)
Messuerotti Alessandra
(M)
Micalizzi Concetta
(M)
Milan Sabrina
(M)
Milocco Cristina
(M)
Mina Tommaso
(M)
Minetti Enrico
(M)
Mongera Nicola
(M)
Nastasi Valentina
(N)
Morabito Lorenza
(M)
Naticchia Alessandro
(N)
Neunhauser Maria
(N)
Onida Francesco
(O)
Paglialonga Fabio
(P)
Palladino Giuseppe
(P)
Pani Antonello
(P)
Pasini Andrea
(P)
Passler Werner
(P)
Peccatori Jacopo
(P)
Piaggio Giorgio
(P)
Pintarelli Giulia
(P)
Pisano Lucia
(P)
Podda Gianmarco
(P)
Polaschi Vera
(P)
Possenti Ilaria
(P)
Potenza Leonardo
(P)
Rampino Teresa
(R)
Ranghino Andrea
(R)
Ravelli Angelo
(R)
Ravera Barbara
(R)
Rigotti Angelo
(R)
Rodrigues Evangeline
(R)
Rona Roberto
(R)
Russo Rodolfo
(R)
Sainati Laura
(S)
Salis Paola
(S)
Salviani Chiara
(S)
Schumacher Fabian
(S)
Seminara Giuseppe
(S)
Somma Chiara
(S)
Stellato Tiziana
(S)
Terruzzi Elisabetta
(T)
Terenziani Monica
(T)
Testa Sara
(T)
Torre Aristide
(T)
Torretta Lorella
(T)
Trenti Chiara
(T)
Trepiccioni Francesco
(T)
Trespidi Laura
(T)
Trisolini Silvia
(T)
Tubaro Martina
(T)
Valentina Pellu
(V)
Vercelloni Paolo
(V)
Verdesca Simona
(V)
Verna Marta
(V)
Verrina Enrico
(V)
Visconti Giuseppe
(V)
Visconti Luca
(V)
Zecca Marco
(Z)
Visconti Luca
(V)
Zecca Marco
(Z)
Minasi Domenico
(M)
Informations de copyright
© 2024. The Author(s) under exclusive licence to Italian Society of Nephrology.
Références
Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C (2017) Haemolytic uraemic syndrome. Lancet 390(10095):648 (PMID: 28242109)
doi: 10.1016/S0140-6736(17)30062-4
George JN, Nester CM (2014) Syndromes of thrombotic microangiopathy. N Engl J Med 371(7):654–666. https://doi.org/10.1056/NEJMra1312353 . (PMID: 25119611)
doi: 10.1056/NEJMra1312353
pubmed: 25119611
Formeck C, Swiatecka-Urban A (2019) Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol 34(8):1337–1348. https://doi.org/10.1007/s00467-018-4039-7 . (PMID: 30109445; PMCID: PMC8627279)
doi: 10.1007/s00467-018-4039-7
pubmed: 30109445
Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, Lommelé Å, Kupelian V, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Licht C, Vande Walle J, Frémeaux- Bacchi V, Global aHUS Registry (2018) Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int 94(2):408–418. https://doi.org/10.1016/j.kint.2018.02.029 . (Epub 2018 Jun 19 PMID: 29907460)
doi: 10.1016/j.kint.2018.02.029
pubmed: 29907460
Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844–1859 ([PubMed:20595690])
doi: 10.2215/CJN.02210310
pubmed: 20595690
pmcid: 2974386
Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschênes G, Lebranchu Y, Zuber J, Loirat C (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8(4):554–562. https://doi.org/10.2215/CJN.04760512.PMID:23307876;PMCID:PMC3613948
doi: 10.2215/CJN.04760512.PMID:23307876;PMCID:PMC3613948
pubmed: 23307876
pmcid: 3613948
Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Frémeaux-Bacchi V (2005) Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 16(2):555–563. https://doi.org/10.1681/ASN.2004050380 . (Epub 2004 Dec 8 PMID: 15590760)
doi: 10.1681/ASN.2004050380
pubmed: 15590760
Cugno M, Berra S, Depetri F, Tedeschi S, Griffini S, Grovetti E, Caccia S, Cresseri D, Messa P, Testa S, Giglio F, Peyvandi F, Ardissino G (2021) IgM autoantibodies to complement factor H in Atypical hemolytic uremic syndrome. J Am Soc Nephrol 32(5):1227–1235. https://doi.org/10.1681/ASN.2020081224.PMID:33712527;PMCID:PMC8259677
doi: 10.1681/ASN.2020081224.PMID:33712527;PMCID:PMC8259677
pubmed: 33712527
pmcid: 8259677
Ardissino G, Salardi S, Colombo E, Testa S, Borsa-Ghiringhelli N, Paglialonga F, Paracchini V, Tel F, Possenti I, Belingheri M, Civitillo CF, Sardini S, Ceruti R, Baldioli C, Tommasi P, Parola L, Russo F, Tedeschi S (2016) Epidemiology of haemolytic uremic syndrome in children. data from the North Italian HUS network. Eur J Pediatr 175(4):465–473. https://doi.org/10.1007/s00431-015-2642-1 . (PMID: 26498648)
doi: 10.1007/s00431-015-2642-1
pubmed: 26498648
Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368(23):2169–2181. https://doi.org/10.1056/NEJMoa1208981 . (PMID: 23738544)
doi: 10.1056/NEJMoa1208981
pubmed: 23738544
Nürnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA, Kribben A, Zimmerhackl LB, Janecke AR, Nagel M, Kirschfink M (2009) Eculizumab for atypical hemolytic- uremic syndrome. N Engl J Med 360(5):542–544. https://doi.org/10.1056/NEJMc0808527 . (Philipp, Thomas[added]. PMID 19179328)
doi: 10.1056/NEJMc0808527
pubmed: 19179328
Gruppo RA, Rother RP (2009) Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 360(5):544–546. https://doi.org/10.1056/NEJMc0809959 . (PMID: 19179329)
doi: 10.1056/NEJMc0809959
pubmed: 19179329
Werion A, Storms P, Zizi Y, Beguin C, Bernards J, Cambier JF, Dahan K, Dierickx D, Godefroid N, Hilbert P, Lambert C, Levtchenko E, Meyskens T, Poiré X, van den Heuvel L, Claes KJ, Morelle J, UCLouvainTMA/HUSNetworkandKULeuvenTMA/HUSNetwork (2023) Epidemiology, outcomes, and complement gene variants in secondary thrombotic microangiopathies. Clin J Am Soc Nephrol. https://doi.org/10.2215/CJN.0000000000000182
doi: 10.2215/CJN.0000000000000182
pubmed: 37094330
Schwotzer N, Frémeaux-Bacchi V, Fakhouri F (2023) Hemolytic Uremic syndrome: a question of terminology. Clin J Am Soc Nephrol. https://doi.org/10.2215/CJN.0000000000000198
doi: 10.2215/CJN.0000000000000198
pubmed: 37249504
Le Clech A, Simon-Tillaux N, Provôt F, Delmas Y, Vieira-Martins P, Limou S, Halimi JM, Le Quintrec M, Lebourg L, Grangé S, Karras A, Ribes D, Jourde-Chiche N, Rondeau E, Frémeaux-Bacchi V, Fakhouri F (2019) Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. Kidney Int 95(6):1443–1452. https://doi.org/10.1016/j.kint.2019.01.023 . (Epub 2019 Mar 15 PMID: 30982675)
doi: 10.1016/j.kint.2019.01.023
pubmed: 30982675
Ardissino G, Cresseri D, Tel F, Giussani A, Salardi S, Sgarbanti M, Strumbo B, Testa S, Capone V, Griffini S, Grovetti E, Cugno M, Belingheri M, Tamburello C, Rodrigues EM, Perrone M, Cardillo M, Corti G, Consonni D, Furian L, Tedeschi S, Messa P, Beretta C (2021) Kidney transplant in patients with atypical hemolytic uremic syndrome in the anti-C5 era: single-center experience with tailored Eculizumab. J Nephrol 34(6):2027–2036. https://doi.org/10.1007/s40620-021-01045-7
doi: 10.1007/s40620-021-01045-7
pubmed: 33956337
Thurman JM (2018) Complement biomarkers of hemolytic uremic syndrome-if not one thing maybe another. Mayo Clin Proc 10:1337–1339. https://doi.org/10.1016/j.mayocp.2018.08.024
doi: 10.1016/j.mayocp.2018.08.024